Baxter International Inc.

BAX • Medical - Instruments & Supplies

$25.83

▲ +0.26 (+1.02%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$13.35B

Growth

2.7%

Cash Flow

5/5

Trend

Stable

Evidence

Positive free cash flow · 0.63Consistent free cash flow · 5/5Healthy liquidity · 2.31Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$25.83

Change1.02%

Shares Out517.00M

Market Cap$13.35B

Enterprise Value$20.87B

52W Range15.73 - 30.00

Beta0.61

P/E-12.56

P/S1.16

P/B2.15

P/FCF42.13

EV/Sales1.82

Price$25.83

Change1.02%

Shares Out517.00M

Market Cap$13.35B

Enterprise Value$20.87B

52W Range15.73 - 30.00

Beta0.61

P/E-12.56

P/S1.16

P/B2.15

P/FCF42.13

EV/Sales1.82

EV/EBITDA89.58

EV/FCF65.84

Earnings Yield-7.96%

FCF Yield2.37%

Dividend Yield1.35%

Gross Margin30.05%

Oper. Margin-2.74%

Profit Margin-8.51%

Debt/Eq1.63

Current Ratio2.31

Quick Ratio1.56

Revenue 5Y2.65%

Target$25.00

Target Upside-3.21%

Target Median$25.00

Target Range21.00 - 28.00

Volume21.06M

Avg Volume6.61M

EPS Surprise0.05

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

62/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

68/100

Why this score▼

Positive free cash flow · 0.63Consistent free cash flow · 5/5Healthy liquidity · 2.31Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

BAX

Analyst sentiment

Based on 36 analyst votes · 2026-09-05

69/100

Neutral

Bullish

Hold

Bearish

Price Target

2026-07-31

Low

$19.00

Mean

$22.86

Median

$24.00

High

$27.00

Company Overview

IPO: 10/27/1981

Industry: Medical - Instruments & Supplies

P/B i: 2.15

Debt / Equity i: 1.63

Operating Margin: -2.74%

Net Margin: -8.51%

ROE i: -

ROIC: -

Financial Health

Score12 / 20

Debt / Equity: 1.63

Current Ratio: 2.31

Quick Ratio: 1.56

Status: Good

Insider Transactions

Recent executive and insider activity

Ampofo William A. II

Transaction: 05/05/2026

BUY

Change

+12,836

Price

Not reported

Filing

05/07/2026

Type

BUY

Craig Jeffrey A

Transaction: 05/05/2026

BUY

Change

+12,836

Price

Not reported

Filing

05/07/2026

Type

BUY

McDonnell Michael R.

Transaction: 05/05/2026

BUY

Change

+12,836

Price

Not reported

Filing

05/07/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Ampofo William A. II	BUY	+12,836	Not reported	05/05/2026	05/07/2026
Craig Jeffrey A	BUY	+12,836	Not reported	05/05/2026	05/07/2026
McDonnell Michael R.	BUY	+12,836	Not reported	05/05/2026	05/07/2026
Shafer David Brent	BUY	+12,836	Not reported	05/05/2026	05/07/2026
MORRISON PATRICIA	BUY	+12,836	Not reported	05/05/2026	05/07/2026
SCHLICHTING NANCY M	BUY	+12,836	Not reported	05/05/2026	05/07/2026
Wendell Amy McBride	BUY	+12,836	Not reported	05/05/2026	05/07/2026
Wilkes David S.	BUY	+12,836	Not reported	05/05/2026	05/07/2026
Teaff James	OTHER	+25,862	$20.37	04/01/2026	04/09/2026
Teaff James	OTHER	0	Not reported	04/01/2026	04/09/2026
Wallace Steven P.	OTHER	+25,862	$20.37	04/01/2026	04/09/2026
Wallace Steven P.	OTHER	0	Not reported	04/01/2026	04/09/2026
Foster Julie	OTHER	+25,862	$20.37	04/01/2026	04/09/2026
Foster Julie	OTHER	0	Not reported	04/01/2026	04/09/2026
Grade Joel T.	SELL	-8,153	$17.69	03/06/2026	03/10/2026
Rasul Reazur	SELL	-12,674	$17.69	03/06/2026	03/10/2026
Rosenbloom David S.	SELL	-6,620	$17.69	03/06/2026	03/10/2026
Soriano Maria Cecilia	SELL	-2,848	$17.69	03/06/2026	03/10/2026
Zielinski Anita A	SELL	-1,932	$17.69	03/06/2026	03/10/2026
Rosenbloom David S.	SELL	-1,336	$19.69	03/02/2026	03/03/2026

About the Company

Baxter International Inc.

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

Source - link

Peers

ATR AVTR BIO DVA HIMS MASI MDGL QGEN RGEN RNA

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Barbara Oil Co. Makes New $853,000 Investment in Baxter International Inc. $BAX

Barbara Oil Co. purchased a new position in Baxter International Inc. (NYSE: BAX) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 40,000 shares of the medical instruments supplier's stock, valued at approximately $853,000. Several other hedge funds also recently made changes

Defense World

Baxter Appoints John Rogers Chief Financial Officer

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed John Rogers as executive vice president and chief financial officer (CFO), reporting to Baxter president and chief executive officer (CEO), Andrew Hider, effective Oct. 1, 2026. “John is a proven global finance executive with extensive operational expertise and a successful track record leading complex transformation initiatives,” said Hider. “He is an ideal fit for.

Business Wire

Baxter Announces Pricing for Its Upsized Cash Tender Offers

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the pricing terms for its previously announced cash tender offers (each, an “Offer” and collectively, the “Offers”) of the Company's validly tendered (and not validly withdrawn) notes set forth below (the “Notes”) using a “waterfall” methodology under which the Company will accept the Notes in order of their respective acceptance priority levels noted in the table below (the “Accep.

Business Wire

Baxter Announces Early Tender Results and Upsizing of Previously Announced Cash Tender Offers

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the early results of its previously announced cash tender offers (each, an “Offer” and collectively, the “Offers”) for its validly tendered (and not validly withdrawn) notes set forth below (collectively, the “Notes”). The Offers are being made pursuant to an Offer to Purchase, dated Aug. 4, 2026 (as it may be amended or supplemented from time to time, the “Offer to Purchase”), whi.

Business Wire

A Look at Baxter International Inc (BAX) After 3.1% Decline -- GF Value $33.00 vs Price $25.91

On August 17, 2026, Baxter International Inc (BAX) shares fell 3.1% to a current price of $25.91. This decline comes amid a 52-week price range of $15.73 to $30

GuruFocus

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-04-30	0.31	0.36	0.05
2026-02-12	0.53	0.44	-0.09
2025-10-30	0.6	0.69	0.09
2025-07-31	0.6	0.59	-0.01
2025-05-01	0.4835	0.55	0.0665
2025-02-20	0.528	0.58	0.052
2024-11-08	0.78	0.8	0.02
2024-08-06	0.662	0.68	0.018
2024-05-02	0.607	0.65	0.043
2024-02-08	0.86	0.88	0.02
2023-11-02	0.66	0.68	0.02
2023-07-27	0.59	0.55	-0.04